Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, Zacks reports.

Citius Oncology Trading Up 1.6%

Shares of NASDAQ CTOR traded up $0.02 during midday trading on Tuesday, reaching $1.27. 375,716 shares of the stock were exchanged, compared to its average volume of 972,712. The stock has a 50 day moving average price of $1.40 and a 200-day moving average price of $1.90. The company has a current ratio of 0.35, a quick ratio of 0.02 and a debt-to-equity ratio of 0.12. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $6.19. The company has a market capitalization of $106.06 million, a P/E ratio of -4.54 and a beta of 2.98.

Institutional Investors Weigh In On Citius Oncology

Several large investors have recently modified their holdings of CTOR. Bank of America Corp DE raised its stake in shares of Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after buying an additional 8,411 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Citius Oncology during the third quarter worth approximately $36,000. Geode Capital Management LLC boosted its holdings in Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after purchasing an additional 36,758 shares during the period. Jane Street Group LLC bought a new position in shares of Citius Oncology in the second quarter worth $465,000. Finally, Armistice Capital LLC bought a new position in shares of Citius Oncology in the 3rd quarter valued at $15,582,000. 70.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CTOR has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday. Maxim Group raised shares of Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, September 23rd. Finally, Citigroup raised Citius Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.